|
|
|
|
||
Consolidated FilingRandom Timeline If data for SAGE-217 for PPD phase 2/3 turns out to be positive (high likelyhood) 4th quarter, and the phase 3 SAGE-217 for MDD also positive, 1st half 2019, then a consolidated filing by the end of 2019 looks quite possible for oral PPD and MDD. This pathway seems to have already been mapped out with the FDA. Potentially, if Bi-Polar Depression works with 217, it could be added to the label of the PPD/MDD indication in 2020. |
return to message board, top of board |